|
|
|
|
New blood pressure drug no help after heart attack
Digg Facebook StumbleUpon Delicious E-Mail to a Friend ATLANTA (Reuters) - The addition of the Novartis blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and...
|
|
|
Novartis drops post-MI development of Tekturna on Phase II failure
Novartis's first-in-class direct renin inhibitor antihypertensive Tekturna (aliskiren) failed to reduce heart remodelling when used as a post-myocardial infarct Novartis drops post-MI development of Tekturna on Phase II failure.
|
|
|
An Aspiring Blockbuster
Novartis (NYSE: NVS) may ASPIRE for great things from blood pressure medication Tekturna, but its latest clinical trial won't help.Perhaps we should have suspected the worst when the company had to stretch to name the trial ASPIRE (Aliskiren Study in...
|
|
|
Tekturna fails to show heart attack benefit
Novartis hypertension treatment Tekturna has failed to show it helps patients recover from a heart attack when added to standard treatment.The 36-week ASPIRE study involve 820 patients and was designed to help limit changes to the hearts shape in...
|
|
|
ACC: Renin Inhibitor Fails to Improve Post-MI Outcomes
Explain to interested patients that this study showed that aliskiren failed to add any benefit to optimal medical therapy for patients recovering from a myocardial infarction.Note that this study was published as an abstract and presented at a conference.
|
|
|
Novartis: Tekturna doesn't help after heart attack
Novartis will not pursue an outcomes trial of its high blood pressure med Tekturna (aliskiren) in combination with standard therapy for heart attack patients after the drug failed to demonstrate a statistically significant benefit in preventing changes in...
|
|
|
UPDATE 1-Novartis drug no help after heart attack-study
ATLANTA, March 16 (Reuters) - The addition of the Novartis blood pressure medicine Tekturna to current standard drugs used to treat patients who had a heart attack failed to help prevent changes in the heart's size and worsening of its blood-pumping...
|
|
|
Novartis' Tekturna Fails In Organ Protection Study
Dow Jones Newswires ZURICH -(Dow Jones)- Novartis AG (NVS) Tuesday said its hypertension drug Tekturna failed to show benefits in an organ protection study that looked at how the medicine affects the heart, dealing a minor setback to efforts to broaden...
|
|
|
Novartis' Tekturna Fails In Organ Protection Study
By Goran Mijuk Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Novartis AG (NVS) Tuesday said its hypertension drug Tekturna failed to show benefits in an organ protection study that looked at how the medicine affects the heart, dealing a minor setback to...
|
|
|
UPDATE 1-Novartis drug no help after heart attack-study
* Tekturna fails as add-on therapy after heart attack * Does not prevent worsening of heart function * Leads to more side effects when used with other drugs (Adds study details, background, researcher comment, byline) ATLANTA, March 16 (Reuters) - The...
|
|
|
Novartis drug fails to help after heart attack: study
ATLANTA (Reuters) - The addition of the Novartis blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening of its blood pumping ability, according to...
|
|
|
Novartis drug fails to help after heart attack: study
24 mins ago ATLANTA (Reuters) The addition of the Novartis blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening of its blood pumping ability,...
|
|
|
Novartis drug fails to help after heart attack: study
ATLANTA (Reuters) - The addition of the Novartis blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening of its blood pumping ability, according to...
|
|
|
Novartis drug fails to help after heart attack: study
ATLANTA (Reuters) - The addition of the Novartis blood pressure medicine Tekturna to current standard drugs in patients who had a heart attack failed to help prevent changes in the heart's shape and worsening of its blood pumping ability, according to...
|
|
|
Novartis drug fails to help after heart attack: study
Tools and articles to help you manage your finances better In addition, patients who got Tekturna on top of current therapy, which includes other types of blood pressure drugs, were more likely to have potentially dangerous levels of potassium in the...
|
